Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Tajeldin Abdallah Mohamed Nour

Tajeldin Abdallah Mohamed Nour

Central Veterinary Research Laboratory (CVRL), Sudan

Title: Camel pox vaccine production in the sudan

Biography

Biography: Tajeldin Abdallah Mohamed Nour

Abstract

The camel Population in the Sudan is about 2.5 million heads and camel pox disease is wide spread and it leads to high economical losses, disease control is also important for camel export. Camel pox vaccine was s produced using a master seed lot which was donated by PANVAC and cultivated on a continuous cell line of African green monkey kidney cell (VERO) and tested for the first time in Sudan. The vaccine was produced according to OIE manual and subjected to potency, safety and efficacy tests in the host animals. The identity test for vaccine virus and locally isolated wild type virus was done as the first step using AGID, VN, and PCR tests. Moreover, sterility test was done for bacterial, mycoplasmal and fungal contaminations. The working seed bank was further tested for safety by inoculation of 6 susceptible camels with 10x the recommended field dose of camel pox vaccine (104 TCID50) using the subcutaneous route .The vaccine efficacy was also demonstrated in 14 healthy susceptible camels. Thus, 10 camels were vaccinated by 103 TCID50 by S/C route and 4 were inoculated with phosphate buffer saline (PBS) and kept as control. The vaccine was safe and the inoculated animals remained healthy without any adverse reaction, neither signs of illness nor a rise in rectal temperature were recorded for up to 40 days post vaccination. Seromonitoring of the vaccinated camels revealed production of protective immune response after the fourth week of vaccination, while control camels did not seroconvert. Forty days post vaccination all the vaccinated and control groups were challenged by 105.6 TCID50 S/C with camel pox. Wild type virus, only the control group developed very severe clinical signs and fever 40oc with generalized and localized camel pox lesions, while the vaccinated groups withstood the test without death or clinical signs. These results confirm that the produced vaccine batch was safe, and immunogenic under laboratory and field trials, which was conducted using 300 camels.